FIELD: medicine.
SUBSTANCE: present invention relates to medicine, namely to oncology, and relates to cancer treatment. For this purpose efficient amount of DMXAA compound (5,6-dimetylxanthenon-4-acetic acid) in combination with inhibitors of vessel endothelium growth factor is introduced.
EFFECT: invention provides for efficient treatment as a result of synergetic antitumor effect of specified preparations.
45 cl, 8 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS (COMPOSITIONS), INCLUDING DMXAA FOR CANCER TREATMENT | 2006 |
|
RU2404765C2 |
| COMPOSITIONS CONTAINING SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | 2002 |
|
RU2333754C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
| SYNERGIC METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2001 |
|
RU2264217C2 |
| COMBINATION AND METHODS FOR INTRODUCING THERAPEUTIC AGENTS AND COMBINED THERAPY | 2006 |
|
RU2452482C2 |
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| COMBINATION TREATMENT | 2014 |
|
RU2666999C2 |
| ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
